Hepion Pharmaceuticals

Company snapshot

Hepion Pharmaceuticals, Inc. (OTCQB:HEPA) is pioneering early cancer detection with novel liquid biopsy diagnostics, on a path toward integrating diagnostics and therapeutics in a closed loop theranostics model. The company is developing first-in-class liquid biopsy tests for hepatocellular carcinoma (HCC) in high-risk patients, with potential applications across other solid tumors. Hepion holds g

• 5 active pipeline program(s) linked via ClinicalTrials.gov.
• 1 US patent(s) indexed to this assignee profile.
• 5 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Hepion Pharmaceuticals. Not investment advice.

Recent activity

Latest pipeline, patent, and corporate events for Hepion Pharmaceuticals.

1. Jun 8, 2026 Clinical update

   CRV431 — Phase 1

2. Jun 5, 2026 Clinical update

   Rencofilstat — Phase 2

3. Jun 5, 2026 Clinical update

   CRV431 75mg — Phase 2

4. May 23, 2026 Clinical update

   rencofilstat, 75 mg — Phase 2

5. May 23, 2026 Clinical update

   [14C]-rencofilstat 225mg — Phase 1

View all clinical trial activity →

• What is Hepion Pharmaceuticals?

  Hepion Pharmaceuticals is a pharma organization headquartered in Morristown, USA. It trades on NYSE under ticker HEPA. Primary therapeutic focus areas include NASH With Fibrosis, NASH - Nonalcoholic Steatohepatitis, Hepatitis B, Nonalcoholic Steatohepatitis (NASH). NovaPharmaNews

• Is Hepion Pharmaceuticals publicly traded?

  Yes. Hepion Pharmaceuticals is listed with ticker HEPA on NYSE per SEC EDGAR records linked on this profile.

• What drugs does Hepion Pharmaceuticals develop or market?

  We link 2 drug profile(s) where Hepion Pharmaceuticals is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/hepion-pharmaceuticals#company-drugs.

• What are the latest developments for Hepion Pharmaceuticals?

  In the last 12 months our linked public records show 5 trial program update(s) and 1 US patent grant(s) tied to this profile.

• What therapeutic areas does Hepion Pharmaceuticals focus on?

  Hepion Pharmaceuticals focuses on NASH With Fibrosis, NASH - Nonalcoholic Steatohepatitis, Hepatitis B based on our analysis of their pipeline programs and drug development activities.